Wound Conforming Matrix Containing Purified Homogenate of Dermal Collagen Promotes Healing of Diabetic Neuropathic Foot Ulcers: Comparative Analysis Versus Standard of Care.

Autor:	Chandler LA; Olaregen Therapeutix, Inc., New York, New York., Alvarez OM; Vascular and Wound Care Center, University Hospital, Newark, New Jersey., Blume PA; Departments of Surgery, Anesthesia, and Cardiology, Yale School of Medicine, New Haven, Connecticut., Kim PJ; Department of Plastic Surgery and Orthopedic Surgery, University of Texas Southwestern Medical Center, Dallas, Texas., Kirsner RS; Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, Florida., Lantis JC; Division of Vascular and Endovascular Surgery, Mount Sinai St. Luke's-West Hospitals, New York, New York., Marston WA; Division of Vascular Surgery, Department of Surgery, University of North Carolina School of Medicine, Chapel Hill, North Carolina.
Jazyk:	angličtina
Zdroj:	Advances in wound care [Adv Wound Care (New Rochelle)] 2020 Feb 01; Vol. 9 (2), pp. 61-67. Date of Electronic Publication: 2019 Dec 18.
DOI:	10.1089/wound.2019.1024
Abstrakt:	Objective: To compare outcomes of diabetic foot ulcers (DFUs) treated with a collagen Wound Conforming Matrix (WCM) or standard of care (SOC). Approach: WCM, a highly purified homogenate of 2.6% fibrillar bovine dermal collagen that conforms to the wound surface, was evaluated in comparison to daily saline-moistened gauze dressing changes (SOC) as part of a retrospective subset analysis of a randomized controlled trial in DFU. Following a 2-week run-in period during which patients received SOC, patients whose wounds did not reduce in area by >30% during run-in were randomly assigned to receive WCM (one or two applications) or SOC. Results: Statistically significant acceleration of early healing rates was observed following a single application of WCM with weekly outer dressing changes compared with daily saline-moistened gauze dressing changes (SOC). Over a 4-week period, 50% of patients receiving a single application of WCM achieved ≥75% reduction in wound area compared with 13% for SOC. WCM appeared to be safe and well tolerated, with no adverse events related to treatment and no evidence of an immunologic reaction to bovine collagen. Innovation: WCM is unique in its intimate contact with the wound bed and its ability to progress a wound toward healing with a single application. Conclusion: WCM is a treatment modality to accelerate DFU healing rates, with the potential to reduce the likelihood of infection and other complications, and cost of care. Competing Interests: L.A.C. is a paid advisor to Olaregen Therapeutix. O.M.A., P.A.B., P.J.K., R.S.K., J.C.L., and W.A.M. have no conflict of interest to declare. The content of this article was expressly written by the authors listed. No ghostwriters were used to write the article. (© Lois A. Chandler, et al. 2019; Published by Mary Ann Liebert, Inc.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu